Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells.

Stem Cells Int · 2013 · PMC3655659 · PMID 23737803

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A greater proportion of patients receiving CD34 + CXCR4 + cells improved LVEF at 6 months (51%), compared to 39% of those receiving unselected cells and 36% for controls; however, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.